Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Aclaris Therapeutics

Aclaris Therapeutics (NASDAQ: ACRS) insider transactions

In the twelve months to 10 November 2026, executives and directors of Aclaris Therapeutics reported 1 open-market sale of 300,000 shares ($1.4m) and 0 open-market purchases, by 1 person, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Aclaris Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
1 August 2026Kolbeck Roland WilhelmChief Scientific OfficerOption exercise+36,375—36,375Form 4
1 August 2026Kolbeck Roland WilhelmChief Scientific OfficerShares withheld for tax−12,385$5.2023,990Form 4
5 June 2026Schiff Andrew NDirectorOption exercise+11,580—25,540Form 4
5 June 2026Milano VincentDirectorOption exercise+11,580—28,896Form 4
5 June 2026Gowen MaxineDirectorOption exercise+11,580—33,334Form 4
5 June 2026Mehra AnandDirectorOption exercise+11,580—726,403Form 4
5 June 2026Molineaux Christopher P.DirectorOption exercise+11,580—69,536Form 4
5 June 2026Humphries William D.DirectorOption exercise+11,580—45,105Form 4
1 May 2026Hall Jesse WayneChief Medical OfficerOption exercise+36,375—36,375Form 4
1 May 2026Hall Jesse WayneChief Medical OfficerShares withheld for tax−9,330$4.4127,045Form 4
23 April 2026Leonard Braden Michael—Open-market sale−300,000$4.5313,950,000Form 4
1 March 2026Balthaser KevinChief Financial OfficerOption exercise+2,375—188,130Form 4
1 March 2026Balthaser KevinChief Financial OfficerShares withheld for tax−677$2.87187,453Form 4
3 February 2026Walker NealCEOOption exercise+63,475—1,562,497Form 4
3 February 2026Walker NealCEOShares withheld for tax−18,611$3.471,543,886Form 4
3 February 2026Loerop JamesChief Business OfficerOption exercise+20,875—198,197Form 4
3 February 2026Loerop JamesChief Business OfficerShares withheld for tax−5,937$3.47192,260Form 4
3 February 2026Balthaser KevinChief Financial OfficerOption exercise+22,025—192,204Form 4
3 February 2026Balthaser KevinChief Financial OfficerShares withheld for tax−6,449$3.47185,755Form 4
3 February 2026Davis Hugh M.President and COOOption exercise+18,675—45,425Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Aclaris Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.